Brainstorm Cell Therapeutics | BCLI - Equity Capital And Reserves


Brainstorm Cell Therapeutics reported $-11.01M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Biogen USD 18.65B 394.9M Mar/2026
Brainstorm Cell Therapeutics USD -11.01M 1.02M Mar/2026
Cipla INR 344.32B 15.13B Mar/2026
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 95.35M 7.38M Mar/2026
CSL USD 18.66B 2.75B Dec/2025
Cytokinetics USD -826.57M 166.94M Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
Grifols EUR 6.21B 133.12M Dec/2025
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Mesoblast USD 574.68M 22.76M Dec/2025